Freeline Therapeutics
Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.
Freeline Therapeutics has raised €178M across 2 funding rounds from 4 investors, most recently a Series C round in Jul 2020. Based in Stevenage, UK; founded 2015; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€178M
€178,189,593
Funding rounds
2
Investors
4
distinct backers
Active since
2020-07
latest 2020-07
Funding by year
EUR raised per yearFreeline Therapeutics — funding by year — interactive chart.
Data table
| Freeline Therapeutics — funding by year | |
|---|---|
| 2020 | €178M |
Signals
High confidenceRaise-next likelihood9
base rate 50% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Down/flat last round
Exit likelihood11
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▲ 11y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-07-05 | Series C | €71M | Eventide Asset Management,Novo Holdings,Wellington Partners | View deal → |
| 2020-07-05 | Series C | €107M | Eventide Asset Management,Novo Holdings,Syncona Partners,Wellington Partners | View deal → |